

DICOT

# Developing the new generation of potency drugs

A man and a woman are sitting on a rocky beach, looking out at the ocean. The man is wearing a blue hoodie and light-colored pants, and the woman is wearing a light blue long-sleeved shirt and dark pants. They are both looking towards the right side of the frame, where the ocean waves are breaking on the shore. The sky is overcast and grey.

“LIB-01 promises to shift the management paradigm of erectile dysfunction.

It is the first revolutionary molecule to enter the field since the advent of Viagra”

Dr Harin Padma-Nathan

World leading medical expert in male sexual dysfunctions.

Lead Principal Investigator for Viagra and Cialis.

DICOT

# Erectile dysfunction

---

52%  
men affected

50%  
abandon treatment



*Erectile dysfunction causes significant negative impact on quality of life for the affected individual and their partner.*

DICOT

# Need of new improved treatments

---

- Despite success, there are several known drawbacks
- Global experts clearly verify need of new treatments

**Side effects**

**35%  
poor/none  
responders**

**Planning  
required**

DICOT

# Premature ejaculation

---

30%  
men affected



- The most common sexual disorder for men under 40
- Current treatment options are limited and comes with side effects and short duration of action
- A significant proportion of men with erectile dysfunction also experience premature ejaculation

DICOT


# A global market expected to grow significantly

---

8

billion USD

Forecast:  
**+6%**  
CARG



DICOT





# The drug candidate LIB-01

*“Invented by nature.  
Reengineered through science.”*

DICOT

# Background – initial behavioral studies in mice




*Studies performed by Professor Wikberg, at Uppsala University*

DICOT



# Preclinical studies demonstrates a long-term effect > 7 days



Results selected for presentation at:



- Performed by Pelvipharm, a world leading CRO who worked with Viagra
- Proven effect also in rats with diabetes and erectile dysfunction

*"It's established in several studies that LIB-01 truly has an effect. The duration is more than seven days. I am therefore confident that Dicot's drug candidate is effective"*

Professor François Giuliano  
Lead expert/KOL in Sexual Medicine, former ESSM President

DICOT

# Clinical phase 1 trial ongoing: SAD results show very good safety profile

---

- First-in-human trial with primary objective to investigate safety profile
- Both SAD (single ascending dose) and MAD (multiple ascending dose) included
- MAD results will be presented in Q2, 2024



DICOT

# In parallel: preparing for phase 2 trials

---

- Background
  - Phase 2a: demonstrate efficacy in patient groups – proof of concept
  - Phase 2b: conclude lowest possible dose/dose regimen for phase 3 trials
- Target to start phase 2a trial during end of 2024.
- Active work with study design, patient groups, number of participants etc.
- Meeting with FDA planned during summer period.



# Mechanism of action – differentiates from current ED medications

ESSM 2023

Abstract # 250  
The pro-erectile facilitator effect of LIB-01 in anesthetized Wistar rats is likely mainly mediated via an NO/cGMP-independent pathway


24<sup>th</sup> Congress of the European Society for Sexual Medicine  
Diane Gorny<sup>1</sup>, Mahita Razanakolona<sup>1</sup>, Charlotta Gauffin<sup>2</sup>, Delphine Behr-Roussel<sup>1</sup>, François Giuliano<sup>3</sup>, Rana Assaly<sup>1</sup>

ESSM 2023


**METHODS: organ bath experiment on isolated strips of rat corpus cavernosum (CC)** DICOT

- Organ chambers filled with oxygenated physiological salt solution
- Incubation of SAE5 at  $10^{-6}$  and  $10^{-5}$  M
- Evaluation of smooth muscle reactivity on pharmacological and electrical field stimulation (EFS)-induced relaxation:

endothelium-dependent relaxation  
nitrenergic relaxation  
endothelium-independent relaxation



(Lisc, NEJM 2000)



"The fact that we now can postulate that the mechanism of LIB-01 differentiates from current ED drugs is of great importance, and an indication that LIB-01 may represent a new generation of ED drugs"

Professor Francois Giuliano  
urologist specialized in sexual  
medicine

DICOT

# Business strategy

---

- To develop LIB-01 until clinical phase 2a and then accelerate and finance the drug development further together with pharma partners.
- The plan is to launch LIB-01 globally through a collaboration and out-licensing strategy.

**DICOT**



**Partners**

DICOT

# Global patent strategy

---

## Patent portfolio



**Two granted patent families** with market exclusivity for LIB-01  
**Three new applications filed** to extend market exclusivity to 2044

## Long-term IP-strategy



Dicot holds several documented, currently non-patented, IP assets and has a timing strategy for when to turn assets into patents to optimise value




DICOT

# Positioning LIB-01

---

**A new first-line treatment  
with market leading position**

1. Long duration of action –  
**sex without planning**
2. Good safety profile –  
**no disturbing side effects**
3. New mode of action –  
**addressing current  
none/poor responders**



DICOT



# Management

---



**Elin Trampe**  
CEO

Elin has a Master of Science in Industrial Engineering and Management from Linköping University. Elin has held several managerial and international roles in various types of companies and industries, including the global companies Mondelz International and GE Global Operations as well as the pharmaceutical company Oasmia Pharmaceutical AB, where Elin had the role as Chief Technical Officer before joining Dicot. Elin has extensive experience in business development, strategic international partnerships, operational excellence and product development.



**Björn Petersson**  
CFO

Björn Petersson has over 20 years of experience as Chief Financial Officer and from other leading roles. Björn has broad expertise in business administration, financing and business management and has been engaged in several different industries, including Life Science and the companies Karessa, Cavid and NeoDynamics, where several are listed on the stock market. Björn has a BSc in financial management from Stockholm University.



**Mats Silvander**  
CTO

Mats has over 20 years of industry experience as Director of Operations, CTO, Vice President Product Development and Quality Manager in areas such as pharmaceutical manufacturing, supplier management, patent work, and building and developing processes and effective teams. Mats has a PhD in Physical Chemistry and has worked for, among others, Novavax, BioGaia, Paragon Nordic, and Quinnova Pharmaceuticals, Inc.



**Charlotta Gauffin**  
CSO

Charlotta Gauffin has more than 20 years of experience in the pharmaceutical industry from for example Medivir, Biovitrum and Galderma, of which more than 15 years within clinical development. Charlotta has had roles such as Clinical Project Manager, Program Director and Head of Clinical Operations. Charlotta also has experience of medical writing and development of clinical and regulatory documents. Charlotta has a PhD in organic chemistry from Uppsala University.

# Board of Directors

---



**Dr Eva Sjökvist Saers**  
Chairman of the Board

Eva Sjökvist Saers has a PhD in pharmaceutical science from Uppsala University. Among other things, she has held the position as Pharmaceutical Director for R&D at Astra Pain Control and has had different manager positions within AstraZeneca as well as CEO of APL for more than ten years. Eva is currently working as a professional board member for various companies within life science e.g. Alligator Bioscience AB, Apoex AB, Bluefish Pharmaceuticals AB, Empowered Applications AB and Oxcia AB and is the chairman of the strategic innovation program Swelife. She was previously chairman of Apotekarsocieteten and vice chairman of the trade organization SwedenBIO.



**Jan-Eric Österlund**  
Board member

Jan-Eric Österlund has a degree of Master of Science in Engineering from Chalmers University of Technology and a bachelor's degree with a focus on business administration from Uppsala University. He has worked as researcher and teacher at the Stockholm School of Economics where he also was acting professor in business administration. Jan-Eric has a broad industrial experience and has been executive vice President of Statskonsult and of Atomenergi and CEO of Masonite. Jan-Eric formed a private equity group in London and was a board member of Ermitage Ltd. He organized the buyout of HemoCue from Pharmacia and was its chairman. Jan-Eric has been chairman or director of several public companies on stock exchanges internationally in finance, medtech, biotech, engineering, and paper industries, including Investment AB Skrinet, MVI Equity AB and Isofol Medical.



**Dr Per-Göran Gillberg**  
Board member

Per-Göran has 35 years of experience from the pharmaceutical industry. He has extensive experience in pharmacology and neuropharmacology from Kabi, Kabi Pharmacia, Pharmacia & Upjohn and Pharmacia, AstraZeneca and Albireo. Per-Göran is the founder of Albireo AB and was VP Development for Albireo Pharma Inc and its subsidiary Albireo AB and is affiliated with the Division of Translational Alzheimer Neurobiology, Karolinska Institute, Stockholm. Board member of Co-opted to the Center for Alzheimer Research at Karolinska Institute.



**Fredrik Buch**  
Board member

Fredrik's professional activities include medical research and clinical activities, medical R&D in the pharmaceutical industry as well as fund management and venture capital/investments. Fredrik has been active in e.g. Sahlgrenska University Hospital in Gothenburg and the University Hospital in Uppsala. This was followed by a couple of years as Medical Director at Pharmacia/Pharmacia & Upjohn and Svenska Hoechst AB, Squibb AB/Bristol Myers Squibb AB Scandinavia. Fredrik has been Head of SEB Läkemedelsfonder, partner at HealthCap, partner and founder of Brilleon Capital and has been active as a venture consultant for Karolinska Investment Fund. Fredrik Buch has extensive experience from Board work and is currently active in the Boards of e.g. Lobsor Holding AB, Intrace Medical System Inc/Intrace Holding AB, Cytovac A/S, Pila B and Acarix AB.



**Dr Mikael von Euler**  
Board member

Mikael von Euler is a Medical Doctor with a PhD from Karolinska Institutet. Mikael von Euler is a trained oncologist with more than 25 years of experience from the pharmaceutical industry. He previously held the position as Medical Director of Targovax (formerly Oncos Therapeutics), and Senior Vice President of Aprea Therapeutics. He has held several c-level positions in major pharmaceutical companies, for example as Cluster Head at Roche/Genentech, Vice President for GlaxoSmithKline and Global Product Director at AstraZeneca. Board member of Annexin Pharmaceuticals AB.



**Michael Zell**  
Board member

Michael Zell has a master's degree in Economics from the Stockholm School of Economics with an Executive Education from Harvard Business School. He began his professional career with a few years in the navy and at Rederi AB Nordstjernen. Since then, Michael has had a long career at Handelsbanken in several senior positions such as Executive Vice President of the bank and CEO of a number of central subsidiaries. In that capacity, he was part of the bank's Group Management for more than 20 years, with responsibility for the bank's operations in Greater China as the last assignment before his retirement. Since then, Michael has been appointed chairman of the Swedish Ship Mortgage Fund by the government. During 2014-18, he was president of the Royal Swedish Society of Naval Sciences.

# Why invest in Dicot

---



- A novel innovative molecule with potential to revolutionize the ED market.
- Supported by +20 global partners and world leading experts.
- Strong scientific support, i.e. 20 preclinical studies.
- Phase 1 clinical study ongoing and preparation for phase 2 trials started.
- Engaged investor community. Unit issue 2023 subscribed at 110%.
- Committed team with strong focus on commercialization and speed to market.

**DICOT**

**Thank you!**

**[www.dicot.se](http://www.dicot.se)**

DICOT